Attainment of glycaemic goals by step-up therapy with biphasic insulin aspart-70/30 in Japanese type 2 diabetic patients

Hosoi, Yasuhiro; Ohtani, Ken-Ichi; Shimizu, Hiroyuki; Kashima, Kouji; Sato, Noriyuki; Akiyama, Hitoshi; Mori, Masataka

doi:10.1507/endocrj.k10e-307

Cited by 5 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They showed that the cumulative rates of achievement of HbA1c <6.5% and <7.0% were 5.1% and 21.2% with once-daily injection, 21.2% and 39.4% with twice-daily injections, and 28.3% and 48.5% with thrice-daily injections (including that patients dropped out). Recently, Hosoi et al [ 14 ] also demonstrated the efficacy of step-up therapy with BIAsp 30 in Japanese patients with T2DM. They showed that the cumulative rates of achievement of HbA1c <7.0% were 10.3% with once-daily injection, 41.3% with twice-daily injections, and 51.4% with thrice-daily injections.…”

Section: Discussionmentioning

confidence: 99%

A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus

et al. 2014

View full text Add to dashboard Cite

IntroductionWhen insulin treatment is started in patients with type 2 diabetes mellitus (T2DM), there are many regimens that control serum glucose levels to a normal range. Basal-bolus insulin therapy is one of the most effective treatments for improving glycemic control to prevent the progression of diabetic microvascular complications. This study was conducted to determine whether step-up insulin treatment with premixed insulin aspart-30/70 (BIAsp 30) or lispro-50/50 (Mix50) in Japanese patients with type 2 diabetes mellitus could achieve better glycemic control.MethodsIn this open label study, 72 insulin-naïve patients with poorly controlled T2DM (HbA1c ≥8.4%), who had been taking oral antidiabetic drugs for at least 12 months, were randomized to receive BIAsp 30 or Mix50 therapy. Patients started treatment of a pre-dinner injection of each type of insulin (Step 1). At 16 ± 2 weeks, a pre-breakfast injection of each type of insulin was added if HbA1c exceeded 7.4% (step 2). If patients had still not achieved HbA1c <7.4% after an additional 16 ± 2 weeks, a pre-lunch insulin injection was added (step 3). Hypoglycemic episodes were also recorded.ResultsThe cumulative percentages of subjects who achieved HbA1c <7.4% were 36.1% (13/36) for both Mix50 and BIAsp 30 in step 1, 62.9% (23/36) for BIAsp 30 and 52.8% (19/36) for Mix50 in step 2, and 66.7% (24/36) in BIAsp 30 and 72.2% (26/36) in Mix50 in step 3. The achievement rates of HbA1c <7.4% were not statistically different between the two groups. A total of ten hypoglycemic episodes occurred in this study. However, there were no severe hypoglycemic episodes. All cases recovered by taking glucose and drinking juice.ConclusionMix50 step-up treatment has a clinical effect in achieving good glycemic control equal to that of BIAsp 30 treatment.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-014-0078-7) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus

et al. 2014

View full text Add to dashboard Cite

show abstract

“…В исследованиях аналогичного дизайна в Японии [19,20] результаты были следующими. Целевого уровня HbA 1c ≤7,0% в первом исследовании (исходный уровень HbA 1c 9,6%) достигли 51% больных, во втором -49% (исходный уровень HbA 1c 8,9%).…”

Section: начало терапии и титрация дозы новомикс 30unclassified

Ten years of NovoMix 30 in Russian and international clinical practice

Суркова¹

2013

Diabetes mellitus

View full text Add to dashboard Cite

show abstract

“…[71,72] In the study by Hosoi et al,[71] a high baseline HbA 1c level (9.6%) was reflected in a lower proportion of patients reaching target HbA 1c (51% to ≤7.0%) than in the study by Garber et al[70] Similarly, Yoshioka et al[72] reported a 49% achievement rate to HbA 1c ≤7.0% in a population with baseline HbA 1c of 8.9%.…”

Section: Safety and Efficacy Of Biasp 30mentioning

confidence: 99%

Ten Years of Experience with Biphasic Insulin Aspart 30

Liebl

Prusty

Valensi

et al. 2012

Drugs

View full text Add to dashboard Cite

Biphasic insulin aspart 30 (BIAsp 30) includes 30% soluble rapid-acting insulin aspart (IAsp) along with an intermediate-acting 70% protaminated IAsp that provides coverage of prandial and basal insulin in a single injection. As BIAsp 30 has been available internationally for 10 years, this review provides a comprehensive overview of the discovery of BIAsp 30, its pharmacokinetic and pharmacodynamic profile, safety and efficacy outcomes from the clinical trial programme, ‘real-life’ clinical insights provided by observational study data, and cost effectiveness and quality-of-life information. These studies have demonstrated that BIAsp 30 once or twice daily is an appropriate option for insulin initiation. BIAsp 30 also provides a switch option in patients on biphasic human insulin (BHI). Switching from BHI to BIAsp 30 is associated with improved postprandial glucose (PPG) and reduced nocturnal and major hypoglycaemia, although daytime hypoglycaemia is higher with BIAsp 30. Intensification of BIAsp 30 can be achieved by increasing the number of daily doses up to three times daily with meals. Therefore, BIAsp 30 provides an intensification option for individuals who are not achieving control with basal insulin and would prefer the simplicity of a single biphasic insulin instead of progressing to a basal-bolus approach. BIAsp 30 has a simple dose-titration algorithm, which enables patients to effectively self-titrate their insulin dose. Cost-effectiveness analyses have demonstrated that BIAsp 30 is cost effective or dominant compared with BHI 30 or insulin glargine in a number of healthcare settings. In conclusion, BIAsp 30 offers a simple and flexible option for insulin initiation and intensification that provides coverage of both fasting and prandial glucose.

show abstract

Attainment of glycaemic goals by step-up therapy with biphasic insulin aspart-70/30 in Japanese type 2 diabetic patients

Cited by 5 publications

References 6 publications

A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus

A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus

Ten years of NovoMix 30 in Russian and international clinical practice

Ten Years of Experience with Biphasic Insulin Aspart 30

Contact Info

Product

Resources

About